Venex 100 mg contains Venetoclax, an oral targeted anticancer therapy classified as a BCL-2 inhibitor. It is primarily used in the treatment of hematologic malignancies, including chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), particularly in patients with specific genetic profiles or those who are ineligible for intensive chemotherapy. Venetoclax provides a precision-based approach to cancer therapy by directly promoting apoptosis, the programmed cell death of malignant cells, thereby reducing tumor burden.

Venetoclax selectively binds to the B-cell lymphoma-2 (BCL-2) protein, which is overexpressed in many cancer cells and prevents apoptosis. By inhibiting BCL-2, Venex restores the natural cell death pathway, allowing cancer cells to die while sparing normal cells. This mechanism makes Venetoclax highly effective in cancers where BCL-2 overexpression contributes to treatment resistance and disease progression.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Venex 100 mg is indicated for:

• Chronic lymphocytic leukemia (CLL), including cases with 17p deletion or TP53 mutation, in adults.

• Acute myeloid leukemia (AML) in adults who are newly diagnosed and ineligible for intensive chemotherapy, often in combination with hypomethylating agents or low-dose cytarabine.

• Use in combination with other therapies as guided by the treating oncologist and based on current clinical protocols.

Therapeutic Class

• Antineoplastic Agent

• BCL-2 Inhibitor

Pharmacology

Venetoclax is an orally bioavailable small molecule that selectively inhibits the anti-apoptotic protein BCL-2. Inhibition of BCL-2 allows pro-apoptotic proteins to trigger mitochondrial outer membrane permeabilization, leading to cell death. This targeted mechanism promotes rapid clearance of malignant cells, particularly in blood cancers where BCL-2 is overexpressed.

Venetoclax demonstrates predictable pharmacokinetics, with oral absorption and plasma levels supporting once-daily administration. Dose escalation is recommended during initial therapy to reduce the risk of tumor lysis syndrome, a potentially serious complication associated with rapid cancer cell death.

Dosage and Administration

• Venex 100 mg is administered orally once daily, typically as part of a dose-escalation schedule to reach the target therapeutic dose.

• It can be taken with or without food, but adherence to the dosing schedule is critical to maximize efficacy and safety.

• Patients require monitoring for blood counts, renal function, and electrolytes, particularly during initial treatment and dose titration.

• Concomitant medications that affect CYP3A activity may require dose adjustments.

Key Benefits

• Targeted therapy for BCL-2 overexpressing hematologic cancers.

• Effective in high-risk CLL patients and those ineligible for intensive chemotherapy.

• Oral administration for convenience and improved patient compliance.

• Can be combined with other therapies to enhance clinical outcomes.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Risk of tumor lysis syndrome (TLS), especially during treatment initiation or dose escalation; hydration and monitoring are essential.

• Increased susceptibility to infections; patients should be screened and monitored regularly.

• Use with caution in patients with renal or hepatic impairment.

• Not recommended during pregnancy or breastfeeding.

Adverse Effects

Common adverse effects include neutropenia, anemia, thrombocytopenia, diarrhea, nausea, fatigue, and infections. Severe complications may include TLS, febrile neutropenia, and cytopenias requiring dose adjustment or supportive care.

Storage

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.

Venex 100 mg provides a powerful, targeted oral treatment for hematologic malignancies, offering improved survival and disease management in patients with CLL and AML.